Navigation Links
Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections

ZURICH, Switzerland, December 19 /PRNewswire/ -- An exclusive license for the development and commercialisation of a drug delivery system for lung infections in Cystic Fibrosis patients was signed today. As part of the agreement, aRigen Pharmaceuticals Inc., Japan transferred relevant rights to Axentis Pharma AG of Switzerland. The EMEA has already granted orphan drug status to the licensed technology and a phase II clinical trial will be initiated by Axentis Pharma AG in early 2008.

Axentis Pharma AG (Switzerland) and aRigen Pharmaceuticals, Inc. (Japan) announced today the signature of a license agreement for the development of therapy against lung infections in Cystic Fibrosis patients. Under the terms of the agreement Axentis Pharma AG purchased from aRigen Pharmaceuticals, Inc. an exclusive license for the development and commercialisation of ARB-CF0223 worldwide except Japan and Korea. ARB-CF0223 is a fully patented, innovative encapsulating drug delivery system for the treatment of pulmonary infections in patients with Cystic Fibrosis. The system has an improved safety profile, higher efficacy and lower doses, and also reduces the frequency and severity of exacerbations compared to current treatments for pulmonary infections in patients with Cystic Fibrosis. As part of the agreement aRigen Pharmaceuticals, Inc. received shares of Axentis Pharma plus an undisclosed sum in cash.

Jorg Zielasek, President of Axentis Pharma AG, commented that: "The purchase of the license from aRigen Pharmaceuticals grants Axentis the right to further develop and commercialise an extremely promising treatment for chronic lung inflammation, the most severe consequence of Cystic Fibrosis. The agreement means that Axentis can now initiate an immediate phase II clinical trial in Germany. The design of the study has already been approved by the EMEA, which has also granted orphan drug status to ARB-CF0223. This is a very promising prospect for both Cystic Fibrosis patients and investors in Axentis."

Mr. Toru Gensuke Tokoro, President and CEO of aRigen Pharmaceuticals, Inc. adds: "ARB-CF0223 is based on a well-characterised drug, Tobramycin. Utilising synthetic liposomes that contain Tobramycin, a proprietary nebulizer delivers the drug directly to the endobronchial sites of infection in Cystic Fibrosis patients. This results in prolonged, high local drug concentration, which in turn achieves higher efficacy and lower doses. We are pleased that a competent partner such as Axentis Pharma will further develop this promising product."

The drug has already been tested successfully in a phase I single-dose inhalation study. No significant adverse events were observed when the liposomal formulation of Tobramycin was compared with the currently marketed formulation in 24 healthy volunteers who were treated in a crossover fashion.

About Cystic Fibrosis

Cystic Fibrosis (CF) is the most common life-threatening inherited multi-organ disease in Caucasians and is caused by a mutation in the CFTR-gene (cystic fibrosis transmembrane conductance regulator) on chromosome 7. The defective gene leads to viscous secretions and impaired mucociliary clearance. The most devastating clinical consequence of CF and cause of morbidity and mortality is lung involvement. A striking feature of lung involvement is the endobronchial colonisation with the bacterial strain Pseudomonas aeruginosa. Chronic inflammation contributes to obstructive lung disease and tissue destruction leading to bronchiectasis and respiratory failure.

About Axentis Pharma AG (

Axentis Pharma AG is a Swiss biotech company. The company owns proprietary technology used in the treatment of diseases, the etiology of which is misrouted or misfolded proteins, for example, cystic fibrosis, nephrogenic diabetes insipidus, hypercholesterolemia and others. Axentis is managed by a team of experienced entrepreneurs.

About aRigen Pharmaceuticals, Inc. (

aRigen Pharmaceuticals, Inc. is a leading Japanese drug discovery and development company working on new molecular entities for infectious diseases. With a vision of "Discovered in Japan for Global Health" the company discovers pharmaceutical compounds in Japan in cooperation with leading Japanese life scientists, and develops them into innovative drugs for the global population. Several of its development programmes have already advanced to the clinical stage.

For further information please contact:

Axentis Pharma AG:

Leuholz 14, 8855 Wangen, Switzerland,

T +41-44-817-7817,

F +41-44-817-7818,


aRigen Pharmaceuticals, Inc.:

7-3-37/3F, Akasaka, Minato-ku, Tokyo 107-0052, Japan,

T +81-3-3470-3310,

F +81-3-3470-3345,


Copy Editing & Distribution:

PR&D - Public Relations for Research & Development,

Michaela Fritsch,

Campus Vienna Biocenter 2, 1030 Vienna,

T +43-1-505-70-44,


SOURCE Axentis Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
3. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Pharsight Achieves First License Sale for Public-Source Database
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/24/2015)... HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... as the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, ... golf through his or her work with turfgrass. , Clarke, of Iselin, ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th ... Paris from 17 th until 19 th ... leader, has invented the first combined scanner in the world ... scanning surface. Until now two different scanners were required: one ... both on the same surface. This innovation is an ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
Breaking Biology News(10 mins):